Letter from the Editor

Dear Reader,

I hope you will enjoy our Medicom Conference Report of this year’s ASCO GU Symposium.
As usual, I’ll just sample some abstracts as “teasers”:

As you will see, we are coming closer to implementing a personalised medicine approach to prostate cancer, with both new prognostic and predictive markers identified.

LuPSMA has been used in daily practice for years in some European countries – now there’s more evidence that this was/is justified.

A new target, a new conjugate – very promising results in advanced bladder cancer treatment.

This comes at a price – and we are increasingly at odds to pay for. Please read the interesting article on the necessary overhaul of licensing and reimbursement of oncology drugs.

So, how about repurposing a cheap drug? Is there a new role for ACE inhibitors in bladder cancer treatments? It may be a little early for that, as this is retrospective data – and there’s a long history of supposedly promising but finally inefficient repurposed drugs in oncology. Still..

Please enjoy our congress report.

Yours, sincerely,

Stefan Rauh

 

Biography

Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is member of the ESMO Practicing Oncologist’s Working Group since 2011 (chair 2014–2018), member of the ESMO Public Policy Committee, and has been an ESMO Executive Board member in 2015–2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.

Conflicts of interest: Nothing to declare.

Copyright ©2021 Medicom Medische Uitgeverij BV



Posted on 24 March 20217 June 2021